BACE (β-secretase) modulates the processing of APLP2 in vivo

@article{Pastorino2004BACEM,
  title={BACE ($\beta$-secretase) modulates the processing of APLP2 in vivo},
  author={Lucia Pastorino and Annat F. Ikin and Smaragda Lamprianou and Nathalie Vacaresse and Jean-Pierre Revelli and Kenneth A. Platt and Paolo Paganetti and Paul M. Mathews and Sheila Harroch and Joseph D. Buxbaum},
  journal={Molecular and Cellular Neuroscience},
  year={2004},
  volume={25},
  pages={642-649}
}
View on Elsevier
doi.org
106 Citations
Highly Influential Citations
2
Background Citations
29
Methods Citations
3
Results Citations
3

106 Citations

Control of APP processing and Aβ generation level by BACE1 enzymatic activity and transcription
TLDR
It is demonstrated that lower BACE transcription is responsible for the minority of APP undergoing the amyloidogenic pathway and relatively lower Aβ production in the normal conditions, and that a slight increase in BACE1 can induce a dramatic elevation in A β production, indicating that the increase in FASEB can potentially increase neuritic plaque formation in the pathological condition.
BACE2 plays a role in the insulin receptor trafficking in pancreatic ß-cells.
TLDR
BACE2 is presented as an important enzyme in β-cell function as a role for BACE2 in the IRβ trafficking and insulin signaling in human pancreas.
Leaky Scanning and Reinitiation Regulate BACE1 Gene Expression
TLDR
During human BACE1 gene expression, ribosomes skipped some uAugs by leaky scanning and translated an upstream open reading frame, initiated efficiently at the fourth uAUG, and subsequently reinitiated Bace1 translation at the physiological AUG site, resulting in weak expression of B ACE1 under normal conditions.
The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease
TLDR
It is concluded that therapeutic inhibition of BACE1 should be efficacious for AD, although careful titration of the drug dose may be necessary to limit mechanism-based side effects.
An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease
TLDR
Analysis of knockout mice lacking the biosynthetic enzyme for bisecting GlcNAc, GnT‐III (Mgat3), revealed that cleavage of Aβ‐precursor protein (APP) by BACE1 is reduced in these mice, resulting in a decrease in Aβ plaques and improved cognitive function.
Understanding BACE1: essential protease for amyloid-β production in Alzheimer’s disease
TLDR
Current knowledge on BACE1 is presented, discussing its structure, function and complex regulation with a view to understanding Bace1 function in the brain, and BACE 1 as a target in blocking aberrant Aβ production in AD.
Bace1 modulates myelination in the central and peripheral nervous system
TLDR
It is shown that Bace1 regulates the process of myelination and myelin sheath thickness in the central and peripheral nerves and that processed neuregulin-1 regulates myelinations by means of phosphorylation of Akt in myelin-forming cells.
1 α-Secretase processing of the Alzheimer amyloid-β precursor protein and its homolog APLP 2
TLDR
The results show that the stimulated α-site cleavage of APP and APLP2 is regulated by different signaling pathways and that the cleavage is mediated by different enzymes.
Transcriptional and translational regulation of BACE1 expression—Implications for Alzheimer's disease
Role of BACE1 in Cognitive Function, from Alzheimer’s Disease to Traumatic Brain Injury
...
...

References

SHOWING 1-10 OF 44 REFERENCES
BACE1 is the major β-secretase for generation of Aβ peptides by neurons
TLDR
It is established that BACE1 is the principal neuronal protease required to cleave APP at +1 and +11 sites that generate N-termini of Aβ.
Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research
ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site
TLDR
The characterization of a second highly related aspartic proteinase, Asp1, is described as a second β-secretase candidate and has the N-terminal sequence ALEP… , indicating that it has lost the prodomain.
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
TLDR
The findings that BACE is the primary beta- secretase activity in brain and that loss of beta-secretase activity produces no profound phenotypic defects with a concomitant reduction in beta-amyloid peptide clearly indicate that Bace is an excellent therapeutic target for treatment of AD.
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
TLDR
The results indicate that mutations in PS1 that manifest clinically cause a gain of function and that inhibition of PS1 activity is a potential target for anti-amyloidogenic therapy in Alzheimer's disease.
BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein
TLDR
It is shown that BACE2 contributes to Aβ production in individuals bearing the Flemish mutation, and that selective inhibition of these highly similar proteases may be feasible and therapeutically advantageous.
Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation
TLDR
These results provide validation of BACE1 as the major β-secretase in vivo and suggest that therapeutic inhibition of Bace1 for the treatment of Alzheimer's disease may be free of mechanism-based toxicity.
Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
TLDR
Asp 2, a novel transmembrane aspartic protease, has the key activities expected of β-secretase, and mutation of either of the putative catalytic aspartyl residues in Asp 2 abrogates the production of the fragments characteristic of cleavage at the β- secretase site.
Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression.
TLDR
The abundance of A beta 11-40/42 produced by BACE suggests that their roles in AD pathogenesis may be underestimated, and BACE utilizes both full-length APP as well as C99 as substrates for the production of C89.
Expression of human β‐secretase in the mouse brain increases the steady‐state level of β‐amyloid
TLDR
In mice expressing huBACE in addition to human APP wild‐type or carrying the Swedish mutation, the induction of APP processing characterized by elevated C99, C89 and sAPPβ, results in increased brain levels of β‐amyloid peptides Aβ40 and Aβ42 at steady‐state.
...
...